The management of hepatocellular carcinoma (HCC) is complex. Given multiple risk factors, varying presentations, and the significant intrastage heterogeneity, treatment is challenging. Depending on the disease presentation, options may be either curative (resection, transplantation, ablation, and radiation segmentectomy) or palliative (chemoembolization and systemic therapy) in intent. In the article that accompanies this editorial, Li et al¹ report on the role of hepatic arterial infusion chemotherapy (HAIC) as an alternative to chemoembolization (TACE) for the patient population afflicted by large (≥ 7 cm), multifocal HCC.

中文翻译：

---

大型肝细胞癌的肝动脉灌注化疗：准备好迎接黄金时间了吗？

肝细胞癌 (HCC) 的治疗是复杂的。鉴于多种风险因素、不同的表现以及显着的阶段内异质性，治疗具有挑战性。根据疾病表现，选择可能是治愈性（切除、移植、消融和放射肺段切除术）或姑息性（化学栓塞和全身治疗）。在这篇社论的随附文章中，Li 等人¹报告了肝动脉灌注化疗 (HAIC) 作为化疗栓塞 (TACE) 替代方案对患有大型（≥ 7 cm）多灶性 HCC 的患者群体的作用。